Arestin is minocycline hydrochloride 1mg and uses a unique microsphere technology delivery system to kill the bacteria and reduce the inflammation that cause periodontal disease. Arestin requires no preparation and is easy to administer. Arestin microspheres are bioadhesive, bioresorbable polymers in powder form produced by a microencapsulation process. Once Arestin is administered, it immediately adheres to the periodontal pocket. The crevicular fluid hydrolyzes the polymer causing water-filled channels to form inside the microspheres. These holes provide "escape routes" for the encapsulated antibiotic for sustained release. The active drug dissolves and diffuses out of the microspheres through the channels into the surrounding tissue. Eventually, the microspheres are completely bioresorbed. Arestin maintains therapeutic drug concentrations for up to 21 days, and the localized delivery provides an effective drug concentration at the site of infection.
Clinically, the application is so easy. Arestin is supplied in pre-filled cannulas with a special applicator. It looks like a syringe and I always make it a point to tell patients that they are not getting an injection. The cannula is loaded into the applicator and then is placed right into the freshly scaled gingival pocket. That's it — the application time takes about two seconds. You can treat many sites on a single patient with Arestin in just minutes.
How do we know if Arestin works? Recent clinical studies conducted and published on Arestin, the most widely used LAA, have proven that Arestin can reduces pocket depths, but more importantly, improves oral and overall health. It also offers clinicians more choices in where to use a long-acting, locally applied antibiotic. A study by J. Max Goodson, et. al., in the August 2007 Journal of Periodontology indicates the following: Arestin provides very specific periodontal pathogen-fighting activity that reduces the number of "bad" bacteria, while leaving the beneficial bacteria alone while also significantly reducing pocket depth, bleeding on probing and increasing clinical attachment level (CAL) much more so than SRP alone.
Several medical journals have also published articles on the oral-systemic link and leading researchers have stated Arestin improves cardiovascular biomarkers known to cause cardiovascular disease. As consumers learn more about the oral-systemic health connection, they will be much more interested in having needed periodontal therapy, especially if it is minimally invasive. I have already seen the growth of this in my own practice — anyone with heart disease, diabetes, or is pregnant is much more in tune with their periodontal health because of all this press.
Smart Buy Summary: Arestin is part of the fast growing minimally invasive periodontal therapies category and is a must for every single dental office that wants to treat periodontal disease with the latest technology. |